Radiolabelled mIBG in the treatment of neuroblastoma
Authors:
- M.N. GazeMGM.N. Gaze
- T.E. WheldonTWT.E. Wheldon
- 1 January 1996
- journal article
- review article
- Published by Elsevier in European Journal of Cancer
- Vol. 32 (1) , 93-96
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastomaEuropean Journal of Cancer, 1995
- Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131i] metaiodobenzylguanidine: Implications for the targeted radiotherapy of neuroblastomaEuropean Journal of Cancer, 1995
- Multi-modality megatherapy with [131I]metaiodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: Feasibility study of a new strategy for advanced neuroblastomaEuropean Journal of Cancer, 1995
- Imaging and treatment of disseminated neuroblastoma with131I-metaiodobenzylguanidineBritish Journal of Radiology, 1987
- Treatment of neuroblastoma with 131I‐MIBG: Dosimetric problems and perspectivesMedical and Pediatric Oncology, 1987
- Treatment of neuroblastoma with metaiodobenzylguanidine: Results and side effectsMedical and Pediatric Oncology, 1987
- Treatment of neuroblastoma with131I-metaiodobenzylguanidine: The experience of an Italian study groupMedical and Pediatric Oncology, 1987
- 131I‐metaiodobenzylguanidine treatment in neuroblastoma: Report of two casesMedical and Pediatric Oncology, 1987
- Considerations on 131I‐metaiodobenzylguanidine therapy of six children with neuroblastomaMedical and Pediatric Oncology, 1987
- Treatment of neuroblastoma with 131I‐metaiodobenzylguanidine: Experience of the Münster/Kassel groupMedical and Pediatric Oncology, 1987